Xin Lang Cai Jing·2026-01-05 15:01Core Viewpoint - Novo Nordisk is facing challenges in its core market, with a recent departure of its U.S. public affairs head amid a significant global business restructuring aimed at reversing its operational decline [1][4]. Group 1: Leadership Changes - Jennifer Dack, the head of U.S. public affairs for Novo Nordisk, has left the company after over six years, during which she led several high-profile projects [2][5]. - Dack's departure coincides with a broader restructuring initiative led by CEO Mike Dusseldorp, which includes plans to cut 9,000 jobs globally [1][5]. - Chris Perney has been appointed as the interim head of the U.S. public affairs team following Dack's exit [1][5]. Group 2: Market Competition - Novo Nordisk is in fierce competition with U.S. rival Eli Lilly in the lucrative and competitive weight-loss drug market [1][5]. - The company has struggled with slowing sales growth and has faced scrutiny over the pricing and accessibility of its key obesity and diabetes medications in the U.S. market [3][6]. - Novo Nordisk recently launched an oral version of semaglutide, which is part of its strategy to regain market traction [6]. Group 3: Financial Performance - Over the past year, Novo Nordisk has issued multiple profit warnings, resulting in a significant decline in its stock price, which has nearly halved [3][6]. - CEO Dusseldorp is attempting to restore investor confidence by refocusing on core business areas [6].